Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.

In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan ...

Daiichi Sankyo and AstraZeneca’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in ...

June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Investigator-assessed PFS demonstrated a median PFS of 40.7 months for ENHERTU plus pertuzumab compared to 20.7 months for THP (HR 0.49; 95% CI 0.39-0.61; nominal p-value <0.00001). Confirmed ...

Investigator-assessed PFS demonstrated a median PFS of 40.7 months for ENHERTU plus pertuzumab compared to 20.7 months for THP (HR 0.49; 95% CI 0.39-0.61; nominal p-value <0.00001). Confirmed ...